<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37173871</PMID><DateCompleted><Year>2023</Year><Month>06</Month><Day>19</Day></DateCompleted><DateRevised><Year>2023</Year><Month>06</Month><Day>19</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1477-0962</ISSN><JournalIssue CitedMedium="Internet"><Volume>32</Volume><Issue>7</Issue><PubDate><Year>2023</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Lupus</Title><ISOAbbreviation>Lupus</ISOAbbreviation></Journal><ArticleTitle>De novo lupus nephritis after SARS-CoV-2 infection.</ArticleTitle><Pagination><StartPage>893</StartPage><EndPage>899</EndPage><MedlinePgn>893-899</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1177/09612033231175280</ELocationID><Abstract><AbstractText>The relationship between viral infection and onset of autoimmune diseases such as systemic lupus erythematosus remains uncertain. During the COVID-19 pandemic, organ-specific and multisystemic autoimmune phenomena temporally related to the viral infection have been described. Immune dysregulation triggered by the SARS-CoV-2 virus leading to hyperactivation of both the innate and adaptive immune systems contributes to the excessive production of pro-inflammatory cytokines, autoantibodies, and subsequent autoimmune manifestations. We report two patients without known autoimmune diseases who developed lupus nephritis shortly after a documented mild SARS-CoV-2 infection. Together with other similar cases in the literature, the observation supports a viral trigger of the development of systemic lupus erythematosus in susceptible individuals.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mok</LastName><ForeName>Chi Chiu</ForeName><Initials>CC</Initials><Identifier Source="ORCID">0000-0003-3696-1228</Identifier><AffiliationInfo><Affiliation>Department of Medicine, Tuen Mun Hospital, Hong Kong, China.</Affiliation><Identifier Source="RINGGOLD">36658</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chu</LastName><ForeName>Chiu Sum</ForeName><Initials>CS</Initials><AffiliationInfo><Affiliation>Department of Medicine, Tuen Mun Hospital, Hong Kong, China.</Affiliation><Identifier Source="RINGGOLD">36658</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tse</LastName><ForeName>Sau Mei</ForeName><Initials>SM</Initials><AffiliationInfo><Affiliation>Department of Medicine, Tuen Mun Hospital, Hong Kong, China.</Affiliation><Identifier Source="RINGGOLD">36658</Identifier></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>05</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Lupus</MedlineTA><NlmUniqueID>9204265</NlmUniqueID><ISSNLinking>0961-2033</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008181" MajorTopicYN="Y">Lupus Nephritis</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001327" MajorTopicYN="Y">Autoimmune Diseases</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">autoimmunity</Keyword><Keyword MajorTopicYN="N">post-COVID-19</Keyword><Keyword MajorTopicYN="N">systemic lupus erythematosus</Keyword><Keyword MajorTopicYN="N">trigger</Keyword></KeywordList><CoiStatement>The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>6</Month><Day>19</Day><Hour>13</Hour><Minute>8</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>5</Month><Day>13</Day><Hour>15</Hour><Minute>13</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>5</Month><Day>13</Day><Hour>1</Hour><Minute>2</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37173871</ArticleId><ArticleId IdType="pmc">PMC10185477</ArticleId><ArticleId IdType="doi">10.1177/09612033231175280</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Wang J, Jiang M, Chen X, et al.Cytokine storm and leukocyte changes in mild versus severe SARS-CoV-2 infection: review of 3939 COVID-19 patients in China and emerging pathogenesis and therapy concepts. J Leukoc Biol. 2020;108:17&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7323250</ArticleId><ArticleId IdType="pubmed">32534467</ArticleId></ArticleIdList></Reference><Reference><Citation>Nazerian Y, Ghasemi M, Yassaghi Y, et al.Role of SARS-CoV-2-induced cytokine storm in multi-organ failure: molecular pathways and potential therapeutic options. Int Immunopharmacol. 2022;113:109428.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9637536</ArticleId><ArticleId IdType="pubmed">36379152</ArticleId></ArticleIdList></Reference><Reference><Citation>Vahabi M, Ghazanfari T, Sepehrnia S. Molecular mimicry, hyperactive immune system, and SARS-COV-2 are three prerequisites of the autoimmune disease triangle following COVID-19 infection. Int Immunopharmacol. 2022;112:109183.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9393178</ArticleId><ArticleId IdType="pubmed">36182877</ArticleId></ArticleIdList></Reference><Reference><Citation>Gracia-Ramos AE, Martin-Nares E, Hern&#xe1;ndez-Molina G. New onset of autoimmune diseases following COVID-19 diagnosis. Cells. 2021;10:3592.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8700122</ArticleId><ArticleId IdType="pubmed">34944099</ArticleId></ArticleIdList></Reference><Reference><Citation>Iwata S, Tanaka Y. Association of viral infection with the development and pathogenesis of systemic lupus erythematosus. Front Med 2022;9:849120.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8914279</ArticleId><ArticleId IdType="pubmed">35280878</ArticleId></ArticleIdList></Reference><Reference><Citation>Gazzaruso C, Carlo Stella N, Mariani G, et al.High prevalence of antinuclear antibodies and lupus anticoagulant in patients hospitalized for SARS-CoV2 pneumonia. Clin Rheumatol. 2020;39:2095&#x2013;2097.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7251560</ArticleId><ArticleId IdType="pubmed">32462425</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Y, Han T, Chen J, et al.Clinical and autoimmune characteristics of severe and critical cases of COVID-19. Clin Transl Sci. 2020;13:1077&#x2013;1086.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7264560</ArticleId><ArticleId IdType="pubmed">32315487</ArticleId></ArticleIdList></Reference><Reference><Citation>Arrestier R, Bastard P, Belmondo T, et al.Auto-antibodies against type I IFNs in &gt; 10% of critically ill COVID-19 patients: a prospective multicentre study. Ann Intensive Care. 2022;12:121.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9803887</ArticleId><ArticleId IdType="pubmed">36586050</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramos-Casals M, Brito-Zer&#xf3;n P, Mariette X. Systemic and organ-specific immune-related manifestations of COVID-19. Nat Rev Rheumatol. 2021;17:315&#x2013;332.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8072739</ArticleId><ArticleId IdType="pubmed">33903743</ArticleId></ArticleIdList></Reference><Reference><Citation>Zacharias H, Dubey S, Koduri G, et al.Rheumatological complications of covid 19. Autoimmun Rev. 2021;20:102883.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8256657</ArticleId><ArticleId IdType="pubmed">34237419</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahmed S, Zimba O, Gasparyan AY. COVID-19 and the clinical course of rheumatic manifestations. Clin Rheumatol. 2021;40:2611&#x2013;2619.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7968918</ArticleId><ArticleId IdType="pubmed">33733315</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Iorio M, Cook CE, Vanni KMM, et al.DMARD disruption, rheumatic disease flare, and prolonged COVID-19 symptom duration after acute COVID-19 among patients with rheumatic disease: a prospective study. Semin Arthritis Rheum. 2022;55:152025.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9116968</ArticleId><ArticleId IdType="pubmed">35617780</ArticleId></ArticleIdList></Reference><Reference><Citation>Fike A, Hartman J, Redmond C, et al.Risk factors for COVID-19 and rheumatic disease flare in a US cohort of latino patients. Arthritis Rheumatol. 2021;73:1129&#x2013;1134.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8014137</ArticleId><ArticleId IdType="pubmed">33455077</ArticleId></ArticleIdList></Reference><Reference><Citation>Khalid MZ, Rogers S, Fatima A, et al.A flare of systemic lupus erythematosus disease after COVID-19 infection: a case of lupus cerebritis. Cureus. 2021;13:e16104.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8325872</ArticleId><ArticleId IdType="pubmed">34350072</ArticleId></ArticleIdList></Reference><Reference><Citation>Yusuf AS, Cheong XK, Rozita M, et al.A case of lupus nephritis flare-up in severe COVID-19 infection. Med J Malaysia. 2021;76:757&#x2013;761.</Citation><ArticleIdList><ArticleId IdType="pubmed">34508391</ArticleId></ArticleIdList></Reference><Reference><Citation>Alharthy A, Faqihi F, Nasim N, et al.COVID-19 in a patient with a flare of systemic lupus erythematosus: a rare case-report. Respir Med Case Rep. 2020;31:101252.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7557168</ArticleId><ArticleId IdType="pubmed">33078093</ArticleId></ArticleIdList></Reference><Reference><Citation>Mageau A, Ferr&#xe9; VM, Goulenok T, et al.Survival after COVID-19-associated organ failure among inpatients with systemic lupus erythematosus in France: a nationwide study. Ann Rheum Dis. 2022;81:1194&#x2013;1196, annrheumdis-2021-221599.</Citation><ArticleIdList><ArticleId IdType="pubmed">34893471</ArticleId></ArticleIdList></Reference><Reference><Citation>Raghavan S, Gonakoti S, Asemota IR, et al.A case of systemic lupus erythematosus flare triggered by severe coronavirus disease 2019. J Clin Rheumatol. 2020;26:234&#x2013;235.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7493768</ArticleId><ArticleId IdType="pubmed">32826658</ArticleId></ArticleIdList></Reference><Reference><Citation>Naranjo-Mill&#xe1;n JA, Bedoya-Joaqui V, Ca&#xf1;as CA. Systemic lupus erythematosus flare during SARS-CoV-2 infection: report of 3 cases presented during the fourth wave of the pandemic in Colombia. Int J Rheum Dis. 2023. [in press]</Citation><ArticleIdList><ArticleId IdType="pubmed">36880687</ArticleId></ArticleIdList></Reference><Reference><Citation>Schioppo T, Argolini LM, Sciascia S, et al.Clinical and peculiar immunological manifestations of SARS-CoV-2 infection in systemic lupus erythematosus patients. Rheumatology (Oxford). 2022;61:1928&#x2013;1935.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8385869</ArticleId><ArticleId IdType="pubmed">34352079</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonometti R, Sacchi MC, Stobbione P, et al.The first case of systemic lupus erythematosus (SLE) triggered by COVID-19 infection. Eur Rev Med Pharmacol Sci. 2020;24:9695&#x2013;9697.</Citation><ArticleIdList><ArticleId IdType="pubmed">33015814</ArticleId></ArticleIdList></Reference><Reference><Citation>Slimani Y, Abbassi R, El Fatoiki F-Z, et al.Systemic lupus erythematosus and varicella-like rash following COVID-19 in a previously healthy patient. J Med Virol. 2021;93:1184&#x2013;1187.</Citation><ArticleIdList><ArticleId IdType="pubmed">32926434</ArticleId></ArticleIdList></Reference><Reference><Citation>Mantovani Cardoso E, Hundal J, Feterman D, et al.Concomitant new diagnosis of systemic lupus erythematosus and COVID-19 with possible antiphospholipid syndrome. Just a coincidence? A case report and review of intertwining pathophysiology. Clin Rheumatol. 2020;39:2811&#x2013;2815.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7384868</ArticleId><ArticleId IdType="pubmed">32720260</ArticleId></ArticleIdList></Reference><Reference><Citation>Ali R, Mehannek R, Patel A, et al.Systemic lupus erythematosus with hemophagocytic lymphohistiocytosis: is COVID-19 the inciting factor? Cureus. 2021;13:e19657.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8679171</ArticleId><ArticleId IdType="pubmed">34976453</ArticleId></ArticleIdList></Reference><Reference><Citation>Gracia-Ramos AE, Saavedra-Salinas M&#xc1;. Can the SARS-CoV-2 infection trigger systemic lupus erythematosus? A case-based review. Rheumatol Int. 2021;41:799&#x2013;809.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7861004</ArticleId><ArticleId IdType="pubmed">33543338</ArticleId></ArticleIdList></Reference><Reference><Citation>Hali F, Jabri H, Chiheb S, et al.A concomitant diagnosis of COVID-19 infection and systemic lupus erythematosus complicated by a macrophage activation syndrome: a new case report. Int J Dermatol. 2021;60:1030&#x2013;1031.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8251349</ArticleId><ArticleId IdType="pubmed">33864388</ArticleId></ArticleIdList></Reference><Reference><Citation>Zamani B, Moeini Taba S-M, Shayestehpour M. Systemic lupus erythematosus manifestation following COVID-19: a case report. J Med Case Rep. 2021;15:29.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7832415</ArticleId><ArticleId IdType="pubmed">33494816</ArticleId></ArticleIdList></Reference><Reference><Citation>Ali S, Almas T, Zaidi U, et al.A novel case of lupus nephritis and mixed connective tissue disorder in a COVID-19 patient. Ann Med Surg 2022;78:103653.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9034828</ArticleId><ArticleId IdType="pubmed">35495962</ArticleId></ArticleIdList></Reference><Reference><Citation>Kazzi B, Fine D, Geetha D, et al.New-onset lupus nephritis associated with COVID-19 infection. Lupus. 2022;31:1007&#x2013;1011.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9066225</ArticleId><ArticleId IdType="pubmed">35485455</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramachandran L, Dontaraju VS, Troyer J, et al.New onset systemic lupus erythematosus after COVID-19 infection: a case report. AME Case Rep. 2022;6:14.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9010314</ArticleId><ArticleId IdType="pubmed">35475008</ArticleId></ArticleIdList></Reference><Reference><Citation>Metyas S, Chen C, Aung T, et al.Rheumatologic manifestations of post SARS-CoV-2 infection: a case series. Curr Rheumatol Rev. 2022;18:346&#x2013;351.</Citation><ArticleIdList><ArticleId IdType="pubmed">35152867</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim H, Levy DM, Silverman ED, et al.A comparison between childhood and adult onset systemic lupus erythematosus adjusted for ethnicity from the 1000 Canadian Faces of Lupus Cohort. Rheumatology (Oxford). 2019;58, 1393&#x2013;1399.</Citation><ArticleIdList><ArticleId IdType="pubmed">30805629</ArticleId></ArticleIdList></Reference><Reference><Citation>Jakes RW, Bae S-C, Louthrenoo W, et al.Systematic review of the epidemiology of systemic lupus erythematosus in the Asia-Pacific region: prevalence, incidence, clinical features, and mortality. Arthritis Care Res (Hoboken). 2012;64:159&#x2013;168.</Citation><ArticleIdList><ArticleId IdType="pubmed">22052624</ArticleId></ArticleIdList></Reference><Reference><Citation>Hino T, Nishino M, Valtchinov VI, et al.Severe COVID-19 pneumonia leads to post-COVID-19 lung abnormalities on follow-up CT scans. Eur J Radiol Open. 2023;10:100483.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9981527</ArticleId><ArticleId IdType="pubmed">36883046</ArticleId></ArticleIdList></Reference><Reference><Citation>Naqvi AAT, Fatima K, Mohammad T, et al.Insights into SARS-CoV-2 genome, structure, evolution, pathogenesis and therapies: Structural genomics approach. Biochim Biophys Acta Mol Basis Dis. 2020;1866:165878.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7293463</ArticleId><ArticleId IdType="pubmed">32544429</ArticleId></ArticleIdList></Reference><Reference><Citation>Mohkhedkar M, Venigalla SSK, Janakiraman V. Untangling COVID-19 and autoimmunity: identification of plausible targets suggests multi organ involvement. Mol Immunol. 2021;137:105&#x2013;113.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8241658</ArticleId><ArticleId IdType="pubmed">34242919</ArticleId></ArticleIdList></Reference><Reference><Citation>Angileri F, Legare S, Marino Gammazza A, et al.Molecular mimicry may explain multi-organ damage in COVID-19. Autoimmun Rev. 2020;19:102591.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7289093</ArticleId><ArticleId IdType="pubmed">32535095</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang K-T, Hsu B-C, Chen D-Y. Autoimmune and rheumatic manifestations associated with COVID-19 in adults: an updated systematic review. Front Immunol. 2021;12:645013.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7994612</ArticleId><ArticleId IdType="pubmed">33777042</ArticleId></ArticleIdList></Reference><Reference><Citation>Dagan N, Barda N, Kepten E, et al. BNT162b2 mRNA covid-19 vaccine in a nationwide mass vaccination Setting. N Engl J Med. 2021;384:1412&#x2013;1423.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7944975</ArticleId><ArticleId IdType="pubmed">33626250</ArticleId></ArticleIdList></Reference><Reference><Citation>Kouhpayeh H, Ansari H. Adverse events following COVID-19 vaccination: a systematic review and meta-analysis. Int Immunopharmacol. 2022;109:108906.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9148928</ArticleId><ArticleId IdType="pubmed">35671640</ArticleId></ArticleIdList></Reference><Reference><Citation>Fan Y-J, Chan K-H, Hung IF-N. Safety and efficacy of COVID-19 vaccines: a systematic review and meta-analysis of different vaccines at phase 3. Vaccines (Basel). 2021;9:989.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8473448</ArticleId><ArticleId IdType="pubmed">34579226</ArticleId></ArticleIdList></Reference><Reference><Citation>Mok CC, Chan KL, Tse SM. Hesitancy for SARS-CoV-2 vaccines and post-vaccination flares in patients with systemic lupus erythematosus. Vaccine. 2022;40:5959&#x2013;5964.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9444500</ArticleId><ArticleId IdType="pubmed">36085256</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>